Company Overview and News

2
Ramdas Athawale seeks details of loans to SC/STs from banks

2018-06-15 freepressjournal.in
Mumbai: Union minister of state for social justice and employment Ramdas Athawale today met public sector banks to take stock of loans given by them under various government schemes, to the weaker section.
UBNC UDBKL 532483 UBLA UBLS CANBK SBAZ CNRYY

3
UK court orders Vijay Mallya to pay costs to Indian banks

2018-06-15 livemint
London: The UK high court has ordered Vijay Mallya to pay a minimum of £200,000 towards the costs incurred by 13 Indian banks in their legal battle to recover alleged dues. Last month, Judge Andrew Henshaw had refused to overturn a worldwide order freezing Mallya’s assets and upheld an Indian court’s ruling that a consortium of 13 Indian banks, led by State Bank of India (SBI), were entitled to recover funds amounting to nearly £1.
IOB 500116 500469 UDBKL IDBI UBLS FDBAY 532505 FEDA 532388 PNJZY 532461 UBLA FEDS PNB UCOBANK FEDERALBNK SBAZ

1
Reminder of Park National Bank and NewDominion expected merger closing date and election deadline

2018-06-14 globenewswire
NEWARK, Ohio and CHARLOTTE, N.C., June 14, 2018 (GLOBE NEWSWIRE) -- Park National Corporation (Park) (NYSE AMERICAN:PRK) and NewDominion Bank (NewDominion) (OTC PINK:NDMN) -- As previously announced by Park, the merger of NewDominion with and into Park’s subsidiary, The Park National Bank, is expected to close on or about July 1, 2018. The deadline for holders of NewDominion common stock and certain NewDominion equity awards to elect the form of consideration they wish to receive in the merger is 5 p.
UDBKL UBLA UBLS PRK

0
United Bank of India - Cessation

2018-06-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

11
Of leadership crunch and low pay: The talent crisis in public sector banks

2018-06-08 moneycontrol
At a time when a majority of the banking sector is fraught with bleeding balance sheets, at least four public sector banks remain headless.
INDIANB UDBKL IDBI 532418 UBLS 532814 SYNDIBANK 532121 532461 532483 UBLA SBAZ 500116 IBN 532505 CNRYY ICICIBANK 532276 PNJZY 532174 PNB UCOBANK CANBK DENABANK ANDHRABANK

4
FM Piyush Goyal to meet heads of PSU banks on Friday

2018-06-07 moneycontrol
Finance Minister Piyush Goyal will meet heads of public sectors banks (PSBs) based out of western and southern regions tomorrow to resolve various issues concerning them.
IOB 500116 UDBKL IDBI ALBK UBLS 532505 532179 532388 PNJZY 532121 532461 CRPKY UBLA 532480 PNB CORPBANK UCOBANK DENABANK SBAZ

11
Just When They Need Leadership, India's State Banks Are Headless - Bloomberg

2018-06-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
INDIANB SRI UDBKL SREINFRA IDBI 532418 UBLS 532814 532121 532461 532483 UBLA 532480 SIFLY 523756 500116 IBN ALBK 532505 SRIA CNRYY 532179 ICICIBANK PNJZY CRPKY 532174 PNB CORPBANK UCOBANK CANBK DENABANK ANDHRABANK

0
United Bank of India - AGM/Book Closure

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

2
2 Unsung Champions

2018-05-30 seekingalpha
Each month, David Fish produces an updated list of Dividend Champions - companies that have increased dividends for at least 25 consecutive years. Also, his monthly database includes Dividend Contenders (10+ years) and Dividend Challengers (5+ years).
IP UDBKL UBLA LANC INPAP UBLS UBSI

0
United Bank of India posts Rs260.62 crore loss for March quarter

2018-05-28 livemint
Kolkata: United Bank of India on Monday said it had in the March quarter registered a net loss of Rs260.62 crore compared with a profit of Rs73.56 crore in the same period a year earlier because of higher provisioning towards non-performing assets (NPAs).
UDBKL UBLA UBLS

0
United Bank of India - Financial Result Updates

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

0
United Bank of India - Press Release

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
UDBKL UBLA UBLS

5
21 PSBs loses Rs 25, 775 crore to banking frauds in 2017-18, says RTI

2018-05-28 freepressjournal.in
Indore: Twenty-one public sector banks (PSBs) have incurred losses totalling Rs 25,775 crore due to banking frauds in the financial year 2017-18, a Right to Information reply has stated.
INDIANB IOB UDBKL IDBI 532418 UBLS 532814 532388 SYNDIBANK 532121 532461 532483 UBLA 532480 SBAZ UBNC 500116 ALBK 532505 532401 VIJAYABANK CNRYY 532179 532276 PNJZY CRPKY PNB CORPBANK UCOBANK CANBK DENABANK ANDHRABANK

5
21 PSBs lost Rs 25,775 cr in bank frauds in 2017-18: RTI

2018-05-28 moneycontrol
Twenty-one public sector banks (PSBs) have incurred losses totalling Rs 25,775 crore due to banking frauds in the financial year 2017-18, a Right to Information reply has stated.
INDIANB IOB UDBKL IDBI 532418 UBLS 532814 532388 SYNDIBANK 532121 532461 532483 UBLA 532480 SBAZ UBNC 500116 ALBK 532505 532401 VIJAYABANK CNRYY 532179 532276 PNJZY CRPKY PNB CORPBANK UCOBANK CANBK DENABANK ANDHRABANK

4
ED likely to seize Rs 7k-cr Nirav Modi assets soon

2018-05-28 freepressjournal.in
New Delhi : The Enforcement Department (ED) is set to move a special court in Mumbai to seek permission for “immediate confiscation” of about Rs 7,000 crore assets of designer diamond jeweller Nirav Modi under the recently promulgated Fugitive Economic Offenders Ordinance.
UBNC IOB 500116 UDBKL IDBI ALBK 532418 UBLS 532505 532179 532388 SYNDIBANK 532276 CRPKY UBLA 532480 CORPBANK UCOBANK ANDHRABANK SBAZ

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...